Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 14, 2020 - Issue
Submit an article Journal homepage
99
Views
4
CrossRef citations to date
0
Altmetric
Original Research

A New Validated HPLC-MS/MS Method for Quantification and Pharmacokinetic Evaluation of Dovitinib, a Multi-Kinase Inhibitor, in Mouse Plasma

Haitham AlRabiah1 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11459, Saudi Arabia
,
Adnan A Kadi1 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11459, Saudi ArabiaORCID Iconhttps://orcid.org/0000-0001-8115-4228
ORCID Icon,
Haya I Aljohar1 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11459, Saudi Arabia
,
Mohamed W Attwa1 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11459, Saudi ArabiaORCID Iconhttps://orcid.org/0000-0002-1147-4960
ORCID Icon,
Nasser S Al-Shakliah1 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11459, Saudi Arabia
,
Sabry M Attia2 Department of Pharmacology Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi ArabiaORCID Iconhttps://orcid.org/0000-0001-8560-8944
ORCID Icon &
Gamal AE Mostafa1 Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11459, Saudi Arabia;3 Micro-Analytical Laboratory, Applied Organic Chemistry Department, National Research Center, Dokki, Cairo, EgyptCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2912-3173
ORCID Icon show all
Pages 407-415 | Published online: 28 Jan 2020

References

  • RoskoskiR. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol Res. 2015;94:9–25. doi:10.1016/j.phrs.2015.01.00325662515
  • GómezX, ValdezN, ParedesR. Tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an unattended need. Rev Peru Med Exp Salud Publica. 2017;34:349–350. doi:10.17843/rpmesp.2017.342.269029177404
  • HartmannJT, HaapM, KoppHG, LippHP. Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009;10(5):470–481. doi:10.2174/13892000978889797519689244
  • AndréF, BachelotT, CamponeM, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013;19:3693–3702. doi:10.1158/1078-0432.CCR-13-019023658459
  • HasinoffBB, WuX, NitissJL, KanagasabaiR, YalowichJC. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem Pharmacol. 2012;84:1617–1626. doi:10.1016/j.bcp.2012.09.02323041231
  • DubbelmanAC, UpthagroveA, BeijnenJH, et al. Disposition and metabolism of 14 C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012;70:653–663. doi:10.1007/s00280-012-1947-223010851
  • AngevinE, Lopez-MartinJA, LinCC, et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res. 2013;19:1257–1268. doi:10.1158/1078-0432.CCR-12-288523339124
  • AzabAK, AzabF, QuangP, et al. FGFR3 is overexpressed Waldenström macroglobulinemia and its inhibition by Dovitinib induces apoptosis, and overcomes stroma-induced proliferation. Clin Cancer Res. 2011;17:4389–4399. doi:10.1158/1078-0432.CCR-10-277221521775
  • KeamB, KimSB, ShinSH, et al. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer. 2015;121:2612–2617. doi:10.1002/cncr.2940125903089
  • LimSM, ChungWY, NamKH, et al. An open label, multicenter, Phase II study of dovitinib in advanced thyroid cancer. Eur J Cancer. 2015;51:1588–1595. doi:10.1016/j.ejca.2015.05.02026070683
  • WangX, KayA, AnakO, et al. Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib. J Clin Pharmacol. 2013;53:14–20. doi:10.1177/009127001143333023400739
  • KimKB, ChesneyJ, RobinsonD, GardnerH, ShiMM, KirkwoodJM. Faze I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res. 2011;17:7451–7461. doi:10.1158/1078-0432.CCR-11-174721976540
  • DasM, PaddaSK, FrymoyerA, et al. Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: a drug–drug interaction. Lung Cancer. 2015;89:280–286. doi:10.1016/j.lungcan.2015.06.01126149476
  • SarkerD, MolifeR, EvansTJ, et al. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res. 2008;14:2075–2081. doi:10.1158/1078-0432.CCR-07-146618381947
  • US Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine; 2013.
  • KadiAA, AlrabiahH, AttwaMW, AttiaS, MostafaGA. Development and validation of HPLC‐MS/MS method for the determination of lixivaptan in mouse plasma and its application in a pharmacokinetic study. Biomed Chromatogr. 2017;31:e4007. doi:10.1002/bmc.4007
  • AlrabiahH, KadiAA, AttwaMW, MostafaGA. Development and validation of an HPLC–MS/MS method for the determination of arginine-vasopressin receptor blocker conivaptan in human plasma and rat liver microsomes: application to a metabolic stability study. Chem Cent J. 2018;12:47. doi:10.1186/s13065-018-0414-529717376
  • SmithG. European medicines agency guideline on bioanalytical method validation: what more is there to say? Bioanalysis. 2012;4:865–868. doi:10.4155/bio.12.4422533559
  • The United State Pharmacopoeia. Convention. 245th ed. Rockville, MD: United State Pharmacopoeia; 2000:2150.
  • MillerJN, MillerJC. Statistics and Chemometrics for Analytical Chemistry. 5th 428 ed. England: Tottenham; 2005:429.
  • ShabirGA. Validation of high-performance liquid chromatography methods for pharmaceutical analysis: understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. J Chromatography A. 2003;987:57–66.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.